Lista de obras - Martin Šimkovič - Dominio Público Uruguay

Alternating R-CHOP and R-cytarabine is a safe and effective regimen for transplant-ineligible patients with a newly diagnosed mantle cell lymphoma.

artículo científico publicado en 2017

Antibodies against Pneumococcal Capsular Polysaccharides and Natural Anti-Galactosyl (Alpha-Gal) in Patients with Humoral Immunodeficiencies

artículo científico publicado en 2017

Assessment of selected markers of apoptosis and angiogenesis in chronic lymphocytic leukemia

artículo científico publicado en 2013

Efficacy of rituximab in primary immune thrombocytopenia: an analysis of adult pretreated patients from everyday hematological practice

artículo científico publicado en 2012

Experiences in the treatment of refractory chylothorax associated with lymphoproliferative disorders

artículo científico publicado en 2019

Five years of experience with rituximab plus high-dose dexamethasone for relapsed/refractory chronic lymphocytic leukemia

artículo científico publicado en 2015

Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial

artículo científico publicado en 2018

Maintenance rituximab in newly diagnosed mantle cell lymphoma patients: a real world analysis from the Czech lymphoma study group registry

artículo científico publicado en 2018

Potential loss of prognostic significance of minimal residual disease assessment after R-CHOP-based induction in elderly patients with mantle cell lymphoma in the era of rituximab maintenance

scientific article published on 13 September 2018

Practical approach to management of chronic lymphocytic leukemia

artículo científico publicado en 2015

Profiling of biological and environmental risk factors in immunogenetic subgroups of chronic lymphocytic leukemia - Czech national study

artículo científico publicado en 2019

Prognostic relevance of angiopoietin-2, fibroblast growth factor-2 and endoglin mRNA expressions in chronic lymphocytic leukemia

artículo científico publicado en 2014

Prospective observational study in comorbid patients with chronic lymphocytic leukemia receiving first-line bendamustine with rituximab

scientific article published on 15 February 2019

RCD Chemoimmunotherapy For Relapsed Chronic Lymphocytic Leukaemia

artículo científico publicado en 2020

Rituximab in combination with high-dose dexamethasone for the treatment of relapsed/refractory chronic lymphocytic leukemia.

artículo científico publicado en 2012

Rituximab infusion-related toxicity in patients with chronic lymphocytic leukemia

artículo científico publicado en 2015

The outcome of chronic lymphocytic leukemia patients who relapsed after fludarabine, cyclophosphamide, and rituximab

artículo científico publicado en 2013

Therapy-related myeloid neoplasms in epithelial ovarian cancer patients carrying BRCA1 mutation: Report of two cases

scientific article published on 22 August 2011

Treatment of Multifocal Multisystem BRAF Positive Langerhans Cell Histiocytosis with Cladribine, Surgery and Allogenic Stem Cell Transplantation

artículo científico publicado en 2017

Venous thromboembolism in patients with chronic lymphocytic leukemia.

artículo científico publicado en 2015

Zanubrutinib monotherapy for patients with treatment naïve chronic lymphocytic leukemia and 17p deletion

artículo científico publicado en 2020

Lista de obras de Martin Šimkovič

Alternating R-CHOP and R-cytarabine is a safe and effective regimen for transplant-ineligible patients with a newly diagnosed mantle cell lymphoma.

Antibodies against Pneumococcal Capsular Polysaccharides and Natural Anti-Galactosyl (Alpha-Gal) in Patients with Humoral Immunodeficiencies

Assessment of selected markers of apoptosis and angiogenesis in chronic lymphocytic leukemia

Efficacy of rituximab in primary immune thrombocytopenia: an analysis of adult pretreated patients from everyday hematological practice

Experiences in the treatment of refractory chylothorax associated with lymphoproliferative disorders

Five years of experience with rituximab plus high-dose dexamethasone for relapsed/refractory chronic lymphocytic leukemia

Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial

Maintenance rituximab in newly diagnosed mantle cell lymphoma patients: a real world analysis from the Czech lymphoma study group registry

Potential loss of prognostic significance of minimal residual disease assessment after R-CHOP-based induction in elderly patients with mantle cell lymphoma in the era of rituximab maintenance

Practical approach to management of chronic lymphocytic leukemia

Profiling of biological and environmental risk factors in immunogenetic subgroups of chronic lymphocytic leukemia - Czech national study

Prognostic relevance of angiopoietin-2, fibroblast growth factor-2 and endoglin mRNA expressions in chronic lymphocytic leukemia

Prospective observational study in comorbid patients with chronic lymphocytic leukemia receiving first-line bendamustine with rituximab

RCD Chemoimmunotherapy For Relapsed Chronic Lymphocytic Leukaemia

Rituximab in combination with high-dose dexamethasone for the treatment of relapsed/refractory chronic lymphocytic leukemia.

Rituximab infusion-related toxicity in patients with chronic lymphocytic leukemia

The outcome of chronic lymphocytic leukemia patients who relapsed after fludarabine, cyclophosphamide, and rituximab

Therapy-related myeloid neoplasms in epithelial ovarian cancer patients carrying BRCA1 mutation: Report of two cases

Treatment of Multifocal Multisystem BRAF Positive Langerhans Cell Histiocytosis with Cladribine, Surgery and Allogenic Stem Cell Transplantation

Venous thromboembolism in patients with chronic lymphocytic leukemia.

Zanubrutinib monotherapy for patients with treatment naïve chronic lymphocytic leukemia and 17p deletion